IDYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IDYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-04), IDEAYA Biosciences's share price is $38.61. IDEAYA Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.10. Hence, IDEAYA Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for IDEAYA Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 7 years, IDEAYA Biosciences's highest Price-to-Free-Cash-Flow Ratio was 14.29. The lowest was 7.52. And the median was 11.55.
IDEAYA Biosciences's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.60. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.10.
During the past 7 years, IDEAYA Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 12.40% per year. The lowest was 7.00% per year. And the median was 9.70% per year.
The historical data trend for IDEAYA Biosciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | 6.29 | - | - | - |
IDEAYA Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, IDEAYA Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Price-to-Free-Cash-Flow falls into.
IDEAYA Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 38.61 | / | -2.101 | |
= | N/A |
IDEAYA Biosciences's Share Price of today is $38.61.
IDEAYA Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
IDEAYA Biosciences (NAS:IDYA) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of IDEAYA Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Yujiro S Hata | director, officer: President and CEO | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Briseno Andres Ruiz | officer: See Remarks | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Jason Throne | officer: VP, General Counsel | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Paul A. Stone | officer: SVP, General Counsel | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Darrin Beaupre | officer: SVP, Chief Medical Officer | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085 |
Catherine J Mackey | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Michael Anthony White | officer: SVP, Chief Scientific Officer | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Michael P. Dillon | officer: SVP, Chief Scientific Officer | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Susan L. Kelley | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Mark Lackner | officer: SVP, Head of Biology | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Andrew J. Schwab | 10 percent owner, Former 10% holder | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
John D Diekman | 10 percent owner, Former 10% holder | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Scott M Rocklage | 10 percent owner, Former 10% holder | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Co-investors Iv, L.p. | 10 percent owner, Former 10% holder | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
From GuruFocus
By PRNewswire • 10-09-2023
By PRNewswire • 09-11-2023
By PRNewswire • 09-27-2023
By PRNewswire • 12-05-2023
By PRNewswire • 08-01-2023
By GuruFocus Research • 01-18-2024
By PRNewswire • 01-07-2024
By GuruFocus Research • 11-07-2023
By PRNewswire • 09-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.